Minitablets enabling dosing and dose individualization in oral solid dosage forms: a case study with atomoxetine

Dorota Haznar-Garbacz; Piotr Muszyński; Daniel Żakowiecki

doi:10.56782/pps.921

Published : 2026-08-31

Vol. 24 No. 3 (2026)

Minitablets enabling dosing and dose individualization in oral solid dosage forms: a case study with atomoxetine

Dorota Haznar-Garbacz

Piotr Muszyński

Daniel Żakowiecki

DOI: https://doi.org/10.56782/pps.921

Abstract

Minitablets represent a promising oral solid dosage form that allows for a wide range of doses within a single formulation. They are particularly suitable for pediatric and geriatric patients. Their small size facilitates administration by improving swallowability, making them an effective alternative for patients who have difficulty swallowing conventional tablets or capsules. This study describes the composition and manufacturing method of minitablets containing atomoxetine hydrochloride as a model drug. The minitablets were prepared using a direct compression method, utilizing the synergistic action of two fillers/diluents with different deformation properties: plastic microcrystalline cellulose and brittle anhydrous dibasic calcium phosphate. The resulting minitablets demonstrated satisfactory mechanical strength and met the required dosage unit uniformity. They also achieved dissolution rates consistent with the relevant monograph. Comparison with commercially available reference products in the form of hard capsules filled with a powder mixture confirmed the potential of minitablets as an effective alternative form of the drug.

Keywords:

minitablets, atomoxetine, wallowing difficulties, dose flexibility, calcium phosphate

Similar Articles

Lucky Vasave, Shivraj Jadhav, Rushikesh Bachhav, Sunil Mahajan, Deepak Sonawane, Formulation and evaluation of gastro-retentive in-situ gel of anti-ulcer drug misoprostol , Prospects in Pharmaceutical Sciences: Vol. 23 No. 4 (2025)
Sylwester Krukowski, SYNTHESIS AND STRUCTURAL STUDIES OF CALCIUM HYDROXYAPATITES MODIFIED WITH AMINO ACIDS , Prospects in Pharmaceutical Sciences: Vol. 11 No. 7 (2013)
Kinga Kocur, Katarzyna Camlet, Anna Ziobro, Mateusz Ziomek, Wojciech Kaźmierski, Paulina Lis, Jakub Jurek, Anna Lis, Renaissance of Ketamine , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Malgorzata Lasota, Adam Kozik, Milena Serwatka, Anna Wiśniewska, Gold nanoparticles as multifactorial modulators of pancreatic cancer cell behavior , Prospects in Pharmaceutical Sciences: Vol. 24 No. 3 (2026)
Mega Yulia, Yufri Aldi, Hansen Nasif, Fatma Sri Wahyuni, Dachriyanus, Immunoactivities of fractions of Elephantopus scaber linn leaf in NK cells, CD8+ T cells, and perforin , Prospects in Pharmaceutical Sciences: Vol. 23 No. 1 (2025)
Olumide Oluyele, Muftau Kolawole Oladunmoye, Anthony Kayode Onifade, Ayodele Oluwayemisi Ogundare, Phoenix dactylifera seed oil enhanced cellular and humoral immune response in cyclophosphamide-immunosuppressed Wistar rats , Prospects in Pharmaceutical Sciences: Vol. 23 No. 1 (2025)
Uzma Faridi, Anti-cancer activity of phenyl-1,3,5-heptatriyne in human liver cancer , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Katarzyna Łysiak, Anna Łysiak, Barbara Maziarz, Paulina Przywara, Natalia Bogumiłło, Kinga Ściurka, Julia Ignacak, Mikołaj Borek, Oliwia Grzelak, Nausea and vomiting associated with chemotherapy and principles of management in their prevention , Prospects in Pharmaceutical Sciences: Vol. 23 No. 1 (2025)
Aleksandra Mikulska, Arkadiusz Kocur, Pharmacotherapy with high doses of methotrexate (HDMTX) in oncology – how should chemotherapy be conducted based on therapeutic drug monitoring? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 4 (2023)
Błażej Grodner, Małgorzata Jelińska, The method of direct determination of manganese in fresh parsley leaves and roots using capillary electrophoresis method. , Prospects in Pharmaceutical Sciences: Vol. 21 No. 1 (2023)

<< < 1 2 3 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Haznar-Garbacz, D., Muszyński, P., & Żakowiecki, D. (2026). Minitablets enabling dosing and dose individualization in oral solid dosage forms: a case study with atomoxetine. Prospects in Pharmaceutical Sciences, 24(3), 54–63. https://doi.org/10.56782/pps.921

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

1. Goh, H.P.; Sia Heng, P.W/; Liew, C.V. The Effects of Feed Frame Parameters and Turret Speed on Mini-Tablet Compression. J. Pharm. Sci. 2019, 108(3), 1161-1171. DOI: 10.1016/j.xphs.2018.09.005

2. De Souter, L.; Nitert, B.J.; De Beer, T. The effect of material properties and process parameters on die filling using double-tip tooling: A PLS-model-based analysis. Int. J. Pharm. 2025, 671, Art. No: 125229. DOI: 10.1016/j.ijpharm.2025.125229

3. Lura, A.; Breitkreutz, J. Manufacturing of mini-tablets. Focus and impact of the tooling systems. J. Drug Deliv. Sci. Technol. 2022, 72, Art. No: 103357. DOI: 10.1016/j.jddst.2022.103357

4. Page, S.; Rode, T.; Breitkreutz, J.; Wagner-Hattler, L. Minitablets current use and future opportunities – An APV course on manufacturing, packaging, characterization and use of minitablets. Eur. J. Pharm. Biopharm. 2024, 199, Art. No: 114294. DOI: 10.1016/j.ejpb.2024.114294

5. Meruva, S.; Singaraju, A.B.; Vinjamuri, B.P.; Ternik, R.; Stagner, W.C. Current State of Minitablet Product Design: A Review. J. Pharm. Sci. 2024, v113(5), 1123-1154. DOI: 10.1016/j.xphs.2024.02.016

6. Mitra, B.; Thool, P.; Meruva, S.; Aycinena, J.A.; Li, J.; Patel, J.; Patel, K.; Agarwal, A.; Karki, S.; Bowen, W. Decoding the small size challenges of mini-tablets for enhanced dose flexibility and micro-dosing. Int. J. Pharm. 2020, 574, Art. No: 118905. DOI: 10.1016/j.ijpharm.2019.118905

7. Klingmann, V.; Langenickel, T.H.; Meissner.; Meissner T.; Mayatepek E.; Moeltner A.; Breitkreutz J.; Bosse H.M. Acceptability of Multiple Uncoated Minitablets in Infants and Toddlers: A Randomized Controlled Trial. J. Pediatr. 2018, 201, 202-207.

8. Klingmann, V.; Hinder, M.; Langenickel, T.H.; Chen, F.; Khder, Y.; Breitkreutz, J.; Bosse, H.M. Acceptability of multiple coated mini-tablets in comparison to syrup in infants and toddlers: a randomised controlled study. Arch. Dis. Child. 2023, 108(9), 730-735. DOI: 10.1136/archdischild-2022-325264

9. Lopez, F.L.; Ernest, T.B.; Tuleu, C.; Gul, M.O. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert Opin. Drug Deliv. 2015, 12(11), 1727-1740. DOI: 10.1517/17425247.2015.1060218

10. Al-Japairai, K.; Hamed Almurisi, S.; Almonem Doolaanea, A.; Mahmood, S.; Alheibshy, F.; Alobaida, A.; Abdul-Halim, N.; Chatterjee, B. A review on taste masked multiparticulate dosage forms for paediatric. Int. J. Pharm. 2023, 632, Art. No: 122571. DOI: 10.1016/j.ijpharm.2022.122571

11. Klingmann, V.; Linderskamp, H.; Meissner T.; Mayatepek, E.; Moeltner, A.; Breitkreutz, J.; Bosse, H.M. Acceptability of Multiple Uncoated Minitablets in Infants and Toddlers: A Randomized Controlled Trial. J. Pediatr. 2018, 201, 202-207.e1. DOI: 10.1016/j.jpeds.2018.05.031

12. Mitsui, N.; Hida, N.; Kamiya, T.; Yamazaki, T.; Miyazaki, K.; Saito, K.; Saito, J.; Yamatani, A.; Ishikawa, Y.; Nakamura, H.; Nakamura, A.; Harada, T. Swallowability of Minitablets among Children Aged 6-23 Months: An Exploratory, Randomized Crossover Study. Pharmaceutics 2022, 14(1), Art. No: 198. DOI: 10.3390/pharmaceutics14010198

13. Kluk, A.; Sznitowska, M.; Brandt, A.; Sznurkowska K.; Plata-Nazar K.; Mysliwiec M.; Kaminska B.; Kotlowska H. Can preschool-aged children swallow several minitablets at a time? Results from a clinical pilot study. Int. J. Pharm. 2015, 485(1-2), 1-6. DOI: 10.1016/j.ijpharm.2015.02.068

14. Channer, K.S.; Virjee, J.P. The effect of formulation on oesophageal transit. J. Pharm. Pharmacol. 1985, 37(2), 126-129. DOI: 10.1111/j.2042-7158.1985.tb05021.x

15. Evans, K.T.; Roberts, G.M. The ability of patients to swallow capsules. J. Clin. Hosp. Pharm. 1981, 6(3), 207-208. DOI: 10.1111/j.1365-2710.1981.tb00994.x

16. Hey, H.; Jørgensen, F.; Sørensen, K.; Hasselbalch, H.; Wamberg, T. Oesophageal transit of six commonly used tablets and capsules. Br. Med. J. (Clin. Res. Ed.) 1982, 285(6356), 1717-1719. DOI: 10.1136/bmj.285.6356.1717

17. Overgaard, A.B.; Højsted, J.; Hansen, R.; Møller-Sonnergaard, J.; Christrup, L.L. Patients' evaluation of shape, size and colour of solid dosage forms. Pharm. World Sci. 2001, 23(5), 185-188. DOI: 10.1023/a:1012050931018

18. Khan, M.S.; Roberts, M.S. Challenges and innovations of drug delivery in older age. Adv. Drug Deliv. Rev. 2018, 135, 3-38. DOI: 10.1016/j.addr.2018.09.003

19. Aleksovski, A.; Dreu, R.; Gašperlin, M.; Planinšek, O. Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups. Expert Opin. Drug Deliv. 2015, 12(1), 65-84. DOI: 10.1517/17425247.2014.951633.

20. Lura, V.; Lura, A.; Breitkreutz, J.; Klingmann, V. The revival of the mini-tablets: Recent advancements, classifications and expectations for the future. Eur. J. Pharm. Biopharm. 2025, 210, Art. No: 114655. DOI: 10.1016/j.ejpb.2025.114655

21. Giatti, F.; Malavolti, M.; Ferrini, F.; Funaro, C. Taste Masking Minitablets Using a Drum Coater. Tablets & Capsules Magazine. 2020, 18(3). Available at https://www.tabletscapsules.com/3641-Technical-Articles/585212-Taste-masking-minitablets-using-a-drum-coater/ (accessed on June 23, 2025)

22. Liu, F.; Ghaffur, A.; Bains, J.; Hamdy, S. Acceptability of oral solid medicines in older adults with and without dysphagia: A nested pilot validation questionnaire based observational study. Int. J. Pharm. 2016, 512(2), 374-381. DOI: 10.1016/j.ijpharm.2016.03.007

23. Walsh, J.; Ranmal, S.R.; Ernest, T.B.; Liu F. Patient acceptability, safety and access: A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations. Int. J. Pharm. 2018, 536(2), 547-562. DOI: 10.1016/j.ijpharm.2017 F.07.01

24. Gorkem Buyukgoz, G.; Kossor, C.G.; Ji, S.; Guvendiren, M.; Davé, R.N. Dose Titration of Solid Dosage Forms via FDM 3D-Printed Mini-Tablets. Pharmaceutics 2022, 14(11), Art. No: 2305. DOI: 10.3390/pharmaceutics14112305

25. Hejduk, A.; Lulek, J. Dispensing of minitablets - Has the problem been resolved? Int. J. Pharm. 2022, 619, Art. No: 121666. DOI: 10.1016/j.ijpharm.2022.121666

26. Van Riet-Nales, D.A.; Kozarewicz, P.; Aylward, B.; de Vries, R.; Egberts, T.C.; Rademaker, CM.; Schobben, A.F. Paediatric Drug Development and Formulation Design-a European Perspective. AAPS PharmSciTech. 2017, 18(2), 241-249. DOI: 10.1208/s12249-016-0558-3

27. Bredenberg, S.; Nyholm, D.; Aquilonius, S.M.; Nyström, C. An automatic dose dispenser for microtablets--a new concept for individual dosage of drugs in tablet form. Int. J. Pharm. 2003, 261(1-2), 137-146. DOI: 10.1016/s0378-5173(03)00294-1

28. Minitablets: Manufacturing, Characterization Methods, and Future Opportunities | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology n.d. Available online: https://www.americanpharmaceuticalreview.com/Featured-Articles/190921-Minitablets-Manufacturing-Characterization-Methods-and-Future-Opportunities/ (accessed on March 20, 2026)

29. Mechler, K.; Banaschewski, T.; Hohmann, S.; Häge, A. Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol. Ther. 2022, 230, Art. No: 107940. DOI: 10.1016/j.pharmthera.2021.107940

30. Witcher, J.W.; Long, A.; Smith, B.; Sauer, J.M.; Heilgenstein, J.; Wilens, T.; Spencer, T.; Biederman, J. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2003, 13(1), 53-63. DOI: 10.1089/104454603321666199

31. Sauer, J.M.; Ring, B.J.; Witcher, J.W. Clinical pharmacokinetics of atomoxetine. Clin. Pharmacokinet. 2005, 44(6), 571-590. DOI: 10.2165/00003088-200544060-00002

32. Yu, G.; Li, G.F.; Markowitz, J.S. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. J. Child Adolesc. Psychopharmacol. 2016, 26(4), 314-26. DOI: 10.1089/cap.2015.0137

33. Eli Lilly and Company, Strattera (atomoxetine HCl), 2007. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021411s004s012s013s015s021lbl.pdf (accessed on June 23, 2025)

34. Childress, A.C. A critical appraisal of atomoxetine in the management of ADHD. Ther. Clin. Risk Manag. 2015, 12, 27-39. DOI: 10.2147/TCRM.S59270

35. Seabright, J. Strattera dosing guide. 2025. Available at https://www.medicalnewstoday.com/articles/drugs-strattera-dosage (accessed on June 23, 2025)

36. Chalon, S.A.; Desager, J.P.; Desante, K.A.; Frye, R.F.; Witcher, J.; Long, A.J.; Sauer, J.M.; Golnez, J.L.; Smith, B.P.; Thomasson, H.R.; Horsmans, Y. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin. Pharmacol. Ther. 2003, 73(3), 178-191. DOI: 10.1067/mcp.2003.25

37. Münch, J.; Sessler, I.; Bosse, H.M.; Wargenau, M.; Dreesen, J.D.; Loforese, G.; Webb, N.J.A.; Sivasubramanian, R.; Reidemeister S.; Lustenberger, P.; Klingmann, V. Evaluating the Acceptability, Swallowability, and Palatability of Film-Coated Mini-Tablet Formulation in Young Children: Results from an Open-Label, Single-Dose, Cross-Over Study. Pharmaceutics 2023, 15(6), Art. No: 1729. DOI: 10.3390/pharmaceutics15061729

38. Spomer, N.; Klingmann, V.; Stoltenberg, I.; Lerch, C.; Meissner, T.; Breitkreutz, J. Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch. Dis. Child. 2012, 97(3), 283-286. DOI: 10.1136/archdischild-2011-300958

39. Mitra, B.; Chang, J.; Wu, S.J.; Wolfe, C.N.; Ternik, R.L.; Gunter, T.Z.; Victor, M.C. Feasibility of mini-tablets as a flexible drug delivery tool. Int. J. Pharm. 2017, 525(1), 149-159. DOI: 10.1016/j.ijpharm.2017.04.037

40. Buck, J.; Huwyler, J.; Kühl, P.; Dischinger, A. Pediatric Dispersible Tablets: a Modular Approach for Rapid Prototyping. Pharm. Res. 2016, 33(8), 2043-2055. DOI: 10.1007/s11095-016-1946-9.

41. Andersen, B.K. Unique minitablet dispenser meets flexible oral dosing need. ON Drug Delivery Magazine. 2020, 109, 22–24. Available online: https://ondrugdelivery.com/unique-minitablet-dispenser-meets-flexible-oral-dosing-need/ (accessed on 29 September 2025)

42. Salmon Pharma GmbH. Immediate release dosage forms of Atomoxetine. European Patent EP3069715A1, 21 September 2016. Available online: https://patents.google.com/patent/EP3069715A1/en (accessed on 29 September 2025)

43. Zakowiecki, D.; Edinger, P.; Papaioannou, M.; Hess, T.; Kubiak, B.; Terlecka, A. Exploiting synergistic effects of brittle and plastic excipients in directly compressible formulations of sitagliptin phosphate and sitagliptin hydrochloride. Pharm. Dev. Technol. 2022, 27(6), 702-713. DOI: 10.1080/10837450.2022.2107013.

44. Zakowiecki, D.; Kukuls, K.; Cal, K.; Pelloux, A.; Mohylyuk, V. Investigating the Mechanical Behaviour of Viscoelastic and Brittle Pharmaceutical Excipients during Tabletting: Revealing the Unobvious Potential of Advanced Compaction Simulation. Pharmaceutics 2025, 17(12), Art. No: 1606. DOI: 10.3390/pharmaceutics17121606

45. Zakowiecki, D.; Lachmann, M.; Hess, T. Eye on excipients. Tablets Capsul. 2019, 17, 39–43. Available online: https://www.researchgate.net/publication/333207856_Eye_on_Excipients_Tablets_Capsules_Magazine (accessed on 29 September 2025)

46. Worku, Z.A.; Kumar, D.; Gomes, J.V.; He, Y.; Glennon, B.; Ramisetty, K.A.; Rasmuson, Å.C.; O'Connell, P.; Gallagher, K.H.; Woods, T.; Shastri, N.R.; Healy, A.M. Modelling and understanding powder flow properties and compactability of selected active pharmaceutical ingredients, excipients and physical mixtures from critical material properties. Int. J. Pharm. 2017, 531(1), 191-204. DOI: 10.1016/j.ijpharm.2017.08.063.

47. Lindberg, N.O.; Berdal, A.; Enstad, G.; Seifert, E.; Lundstedt, T. Investigation of flow properties of powders by means of a uniaxial tester, in relation to direct tablet compression. Drug Dev. Ind. Pharm. 2002, 28(1), 15-28. DOI: 10.1081/ddc-120001482

48. U.S. Food and Drug Administration. Strattera (atomoxetine) capsules: prescribing information, 2022. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021411s050lbl.pdf (accessed on 9 October 2025).

49. Neuraxpharm. Konaten. Charakterystyka Produktu Leczniczego (ChPL), 2025. Available online: https://static.neuraxpharm.com/wp-content/uploads/sites/18/2025/06/04112358/konaten-chpl.pdf (accessed on 9 October 2025).

50. Wu, Y.; Zhao, F.; Paborji, M. Effect of fill weight, capsule shell, and sinker design on the dissolution behavior of capsule formulations of a weak acid drug candidate BMS-309403. Pharm. Dev. Technol. 2003, 8(4), 379-83. DOI: 10.1081/pdt-120024691

51. Simpson, D.; Plosker, G.L. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004, 64(2), 205-222. DOI: 10.2165/00003495-200464020-00005

52. Lovecchio, F.; Kashani, J. Isolated atomoxetine (Strattera) ingestions commonly result in toxicity. J. Emerg. Med. 2006, 31(3), 267-268. DOI: 10.1016/j.jemermed.2005.12.024

53. Grimm, M.; Koziolek, M.; Kühn, J.P.; Weitschies W. Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water. Eur. J. Pharm. Biopharm. 2018, 127, 309-317. DOI: 10.1016/j.ejpb.2018.03.002

Dorota Haznar-Garbacz

dorota.haznar-garbacz@umw.edu.pl

Affiliation:

a:1:{s:5:"en_US";s:83:"Wroclaw Medical University, Faculty of Pharmacy, Department of Drug Form Technology";} Poland

Piotr Muszyński

Affiliation:

1 Wroclaw Medical University, Faculty of Pharmacy, Department of Drug Form Technology Poland

Daniel Żakowiecki

daniel.zakowiecki@budenheim.com

Affiliation:

Chemische Fabrik Budenheim KG Germany